Inflammatory breast cancer in humans (IBC) is the most aggressive form of mammary gland cancer and shares clinical, pathological and molecular patterns of disease with canine inflammatory mammary carcinoma (CIMC). Despite the use of multimodal therapeutic approaches, including targeted therapies, the prognostic for IBC/CIMC remains poor. The aim of this review is to critically analyze IBC and CIMC in terms of biology and clinical features. While rodent cancer models have formed the basis of our understanding of cancer biology, the translation of this knowledge into improved outcomes has been limited. However, it is possible that a comparative "one health" approach to research, using a natural canine model of the disease, may help advanced our knowledge on the biology of the disease.
Introduction
Dogs spontaneously develop cancers that share the biology and heterogeneity of cancers found in humans, including many clinical, molecular and pathological characteristics.
Canine cancers are often relatively large tumors that develop spontaneously in large outbred mammals; are genetically complex and diverse; exist in the presence of an intact immune system, with complex interactions between the host immune system and tumor cells; have significant tumor heterogeneity both within patients and between patients; develop therapeutic resistance and metastasize to distant sites. The natural history and potential clinical use of cancers in companion dogs in general is out of the scope of this review, and have been extensively reviewed elsewhere [1] [2] [3] [4] .
Inflammatory breast cancer in humans (IBC) and the corresponding canine disease, canine inflammatory mammary carcinoma (CIMC), are the most aggressive type of mammary cancer in both species with short survival times after diagnosis [4] [5] [6] . In humans, IBC was first described in 1814 by Charles Bell as a painful breast tumor with a poor prognosis, presenting purple discoloration of the overlying skin [7] . In 1924 the designation "inflammatory breast cancer" was applied by Lee and Tannenbaum, who provided a clinical description of the malignancy [8] . IBC is a rare and highly metastatic type of breast cancer comprising less than 3% of human breast cancer cases in the USA [9] with higher incidence observed in Northern Africa where the incidence varies from approximately 7% in Tunisia [10] to 11% in Egypt [11] . The reasons of such high incidence in this part of the world remain unknown. IBC is primarily a clinical adjunct to the histopathological diagnosis of breast cancer. IBC presents unique histopathological and clinical features for both humans and animals: edema, erythema, firmness, painful sensation, warmth of the mammary glands coupled with histological confirmation of tumor invasion of dermal lymphatic vessels [12, 13] . Inflammatory mammary carcinoma in companion animals was initially described in dogs [14] and more recently in cats [15] . In a study at the Complutense University in Madrid, Spain, the reported prevalence of CIMC among dogs presenting for local consultation with mammary gland tumors and dysplasias was reported to be 7.6% [16] . Based on clinical and histological similarities, the possibility of using CIMC as a model to study IBC has been proposed by several authors [16] [17] [18] [19] . The comparative aspects between IBC and CIMC including the etiology, molecular biology, diagnosis, treatment and prognosis, supporting the rationale for using CIMC as a model for IBC are summarized and analyzed in Table 1 [6,14,20 -52] . The effect of hormones on the etiology of CIMC and IBC is summarized in Table 1 Comparative aspects between IBC and CIMC, including the etiology, molecular biology, diagnosis, treatment, and prognosis, supporting the rationale for using CIMC as a model for IBC. CIMCComments Reference Clinical signs  Edema, erythema, firmness, warmth, pain [14] Diagnosis  Clinical signs and invasion of dermal lymphatic vessels  Dermal lymphatic vessel invasion is a hallmark of CIMC [20] 
Viral etiology
 Not yet investigated in CIMC. Absence of MMTV does not support a role in non-CIMC.
[21]
Cytokine activity  Serum levels of IL-10, IL-8 increased in CIMC vs non-CIMC.  Reduced case number (N=7) [22] Molecular profiling [23]
[24]
[25]
Therapeutic options
 Surgical excision without diffuse presentation  Chemotherapy + Piroxicam  Only small case series have been reported, no clinical trials have been performed.
[26] [6] Prognostic factors  Administration of medical treatment extends survival, but not significantly  Prognostic studies on CIMC are difficult to perform as most animals are euthanised due to the severity of disease, thus the cause of death is not advanced metastatic disease.
[6]
IBC

Clinical signs
 Edema, erythema, "Peau d'orange", discoloration, firmness, pain.
Diagnosis  Clinical signs and dermal lymphatic vessels invasion  Although very frequent, invasion of lymphatic dermal vessels is not specific.
[28]
Viral etiology
Human papilomavirus (HPV) Human cytomegalovirus (HCMV)  Human mammary tumor virus  Although there is an association between viral titers and the biological aggressiveness of IBC, a causal relationship is still debated.
[29] [30] [31,32] Cytokine activity  TNF, IL-10, IL-8  The cytokine activity was measured in conditioned media of CD14 + PBMCs collected from axillary vein tributaries of IBC patients during surgery, but not in the serum.
[33]
Molecular profiling
Sialyl Lewis underexpression and E-cadherin overexpression Overexpression of NF-κB target genes WISP3 inhibition and RhoC GTPase activation, which controls proliferation and invasion  COX-2 expression in IBC remains unstudied, with the exception of vitro studies on celecoxib resistant cell line SUM149-CER [34] and the role of COX-2-produced 
Etiology
Endocrine etiology
The etiology of both IBC and CIMC is multifactorial, resulting from a combination of hormonal changes, accumulated genetic mutations [5] and environmental factors [61] [62] [63] .
Several studies have been performed using canines to detect the expression of steroid hormones and their receptors that could be implicated in the genesis of the abnormal mammary epithelial proliferation observed in CIMC and in canine mammary tumors overall [53] [54] [55] . Expression of estrogen receptor alpha (ER), estrogen receptor beta (ERβ) and androgen receptor (AR) was evaluated by immunohistochemistry in a series of CIMC and non-CIMC tumors [54] . In all CIMC cases (N=14), ER expression was absent and 13/14 (93%) of cases were ERβ and also AR positive. Moreover, AR expression in CIMC was increased relative to non-CIMC and normal mammary gland [54] . A more recent study [56] , using a quantitative scoring system generated by adding the percentage of positive cells and the intensity of immunolabelling (total score expressed as mean ± S.E.M.) showed significant increases in immunohistochemistry staining for aromatase (P=.025), an enzyme that converts androgens to estrogens in situ [64] , and also ERβ (P=.038) and progesterone receptor (PR) (P=.0037) in CIMC (n=21) versus non-CIMC (n=19). However no differences were found for expression of AR between CIMC and non-CIMC [56] . This disparity in AR results studies [54, 56] could be explained by the differences in scoring systems and tumor series used, as well as by an increase in the conversion of androgens to estrogens in CIMC through abundant aromatase expression and subsequent down-regulation of AR in the study by de Andres et al.
Hormone serum levels of dehydroepiandrosterone, androstenedione, testosterone, progesterone and estrone sulfate were significantly higher in CIMC than in non-CIMC samples [53, 54] . The abundance of steroid hormones might be an important contributing factor in the pathogenesis of CIMC by mechanisms of paracrine and/or autocrine action.
Estrone sulfate in particular may be converted into estrone and estradiol by the enzyme steroid sulfatase [65] or can directly transactivate estrogen and androgen receptors [66] therefore magnifying the effects of steroid hormonal regulation in CIMC.
In IBC, to the best of our knowledge, detailed imunoexpression of ER and β, AR and aromatase have not yet been reported in the literature. Of note, steroid hormones levels, including progesterone, androstenedione, testosterone, 17β-estradiol and estrone sulfate levels have been shown to be higher in the conditioned media of the IBC cell line SUM149 than in the CIMC cell line IPC-366 by ELISA immunoassay [67] . This study demonstrated in vitro secretion of steroid hormones (progesterone, androstenedione, testosterone, 17β-estradiol and estrone sulfate) [67] , suggesting a role for hormonal regulation in IBC.
However, studies with clinical samples, including tumor tissue and serum from patients with non-IBC and patients with IBC would be required to confirm this hypothesis and overcome the inherent limitations associated with in vitro conditions.
Viral etiology
Regarding the role of infectious agents in the etiology of breast cancer, viral infections by high-risk human papillomavirus (HPV) have been identified in metaplastic mammary carcinomas [30] , but a causal relationship has not been established. In patients with IBC, titers of human cytomegalovirus (HCMV) IgG antibodies were found to be higher than in non-IBC patients. The presence of HCMV has been suggested to be linked to the etiology and pathogenesis of IBC with HCMV playing an oncomodulatory role by infecting adjacent tissues, leading to overexpression and activation of NF-κB/p65 [29, 68, 69] . To support this hypothesis, A recent study that enrolled 91 patients with non-IBC and 44 with IBC reported DNA from HCMV and HPV-16 were the most detected viral DNAs in breast carcinoma tissues, although the frequency and prevalence of HCMV and human herpes virus type 8 (HHV-8) DNA were significantly higher in IBC than non-IBC tissue [70] . However, the high incidence found in this study could be due to cross-contamination during the handling and processing of tissue samples, and the isolation of viral DNA, as the measures to prevent cross-contamination were not disclosed, therefore casting doubt on its results. The absence of papillomavirus DNA has been confirmed in normal canine mammary gland (N=5) and canine mammary tumors (CMT) (N=27). Whilst this suggests these viruses are not associated with canine mammary carcinogenesis, the small numbers of cases studied makes it impossible to rule out [71] .
Mouse mammary tumor virus-like sequences (MMTV) have been associated with human breast cancer [72] [73] [74] . These sequences were also found in CMT at similar frequencies in normal, benign and malignant CMTs, suggesting that MMTV is not causally associated with CMT [21] . Overall, the involvement of viruses in breast cancer, including IBC, remains unclear [75, 76] . Given the influence of viruses in cancer [77] , and in particular the oncogenic role of MMTV in murine mammary carcinogenesis [78] [79] [80] , further research is warranted to determine the possible role of viruses in the malignant transformation of mammary gland cells of both dogs and humans.
Molecular biology of Inflammatory Breast Cancer
Inflammatory microenvironment
During carcinogenesis, malignant transformation is triggered by the accumulation of DNA mutations [81] . Some have suggested the high level of inflammation observed in IBC may serve to increase genetic instability and its associated DNA damage, promoting the malignant phenotype by increasing mutation rates [82, 83] .
Considering IBC or CIMC as types of cancer with flaring inflammation, the expression of diverse cytokines and inflammatory mediators has been evaluated to determine their role in the severity of the disease. In CIMC, a study analyzing the presence of several cytokines in the serum and tissue homogenates of CIMC (n=7), malignant non-CIMC (n=24), mammary-gland hyperplasia (n=7) and benign tumors (n=10) reported higher IL-10 and IL-8 serum levels in CIMC tumors than in the other groups, whereas in tumor-tissue homogenates, only IL-10 was significantly higher in CIMC than in the other groups, indicating a role for immunosuppression in the progression of CIMC [22] . One of the main limitations of this study was the low number of tumors present in each of the groups considered. These comparable observations suggesting a role for inflammatory cell infiltration and cytokine production in IBC and CIMC contribute to the growing body of evidence suggesting the value of CIMC as a model for the corresponding human disease [17] . The concept of TAMs and tumor-infiltrating T-cells as important elements in the establishment of a tumor-favorable microenvironment is also strengthened. Research on the role of cytokines and chemokines in the biological behavior of both IBC and CIMC could contribute to a better understanding of this disease and lead to the development of more efficient, targeted therapies to improve the current standard of care.
Epithelial to mesenchymal transition (EMT)
Extensive metastasis is a prominent aspect clinical progression of IBC and it is hoped that this will provide a target for novel therapies. Studies performed in IBC have explored the process of metastasis and the potential to identify new targets for intervention [36, 37] with a focus on the mechanisms involved in epithelial to mesenchymal transition (EMT).
TGF-β is a major inducer of EMT during embryological development, cancer and diseases involving chronic wound healing or fibrosis [85] . In response to TGF-β, many transcription factors regulating EMT are activated, including Twist1, SMAD, Zeb1 and 2 and Snail1 and 2 [85] . In IBC, however, EMT does not seem to have an important role in the process that enables cell migration and metastasis, given the lower levels of expression of TGFβ and the SMAD transcription factor in IBC versus non-IBC samples [60, 86] .
One hypothesis to explain the apparent EMT-independent migration and metastasis of IBC is that attenuation of TGF-β and in turn SMAD signaling causes a shift from singlecell motility to a cohesive type of cluster migration with clustering mediated by E-Cadherin, leading primarily to the invasion of lymph vessels [60] . This hypothesis is supported by the differential expression of E-cadherin and the mechanisms involved in the cohesion of cells within emboli. E-cadherin overexpression is present in IBC models such as SUM149 and Mary-X, and constitutes part of a defined IBC molecular signature [36, [87] [88] [89] [90] [91] .
Overexpression of E-cadherin in IBC is seen in lymphovascular tumor emboli and in infiltrating tumor cells and seems to be involved in a metastatic process in which cohesion of cell clusters increases metastasis [37] .
To confirm E-cadherin overexpression is responsible for the tight junctions inside of clusters, investigators used Mary-X, a human xenograft model of IBC, to show that Ecadherin membrane expression contributes to an oncogenic effect while promoting metastasis instead of suppressing it [92] . Specifically they observed the mechanism of E-cadherin overexpression was not transcriptional but instead related to altered protein trafficking. Ecadherin protein levels were 5-to 10-fold higher, but real-time RT-PCR, demonstrated Ecadherin transcript levels in Mary-X were 3-to 11-fold less than in other E-cadherin positive human breast carcinoma lines These observations suggested altered E-cadherin trafficking contributes to its oncogenic rather than suppressive role in IBC.
Cooperation between Sialyl Lewis x/a (sLe x/a ) under-expression and E-cadherin overexpression provided a molecular explanation for the formation of the lymphovascular emboli in the Mary X IBC model. Low sLe x/a expression impedes adherence to the lymphovascular endothelium, and thus allows mobility of cell clusters. At the same time, the lack of electrostatic repulsion between sLe x/a epitopes favors the maintenance of E-cadherin homodimers between cells increasing cellular cohesion [36] .
In CIMC cell lines, there has been limited characterization of sLe x/a expression, but in the recently established IPC-366 CIMC cell line, E-cadherin and COX-2 overexpression were coupled with high proliferation rates, negative hormone receptors (PR, ER) and HER2 [23] . In humans, COX-2 overexpression has been detected in the IBC cell line SUM149 and, it is suggested to drive celecoxib resistance in this cell line [34] . Comparative molecular biology aspects of CIMC and IBC are summarized in Table 3 [22, 33, 36, 84, 85, 91, 93] . 
Clinical Presentation and Pathologic/Histologic Findings
In humans, IBC is a clinical diagnosis characterized by a rapid enlargement of the breast, changes in the overlying skin, with early erythematous discoloration and an orangepeel appearance due to dermal edema (peau d'orange) with or without underlying discrete or palpable masses [46] (Figures 1A, B, C) . These signs often cause misdiagnosis of an inflammatory or infectious process [27] . As in human IBC, the clinical presentation of CIMC can be wrongly diagnosed as mastitis or dermatitis due to extensive inflammation of the skin overlying the mammary glands, edema, as well as the pain involving the the axillary, mammary and inguinal regions ( Figure 1D, E, F) . Signs of generalized weakness, anorexia and metastasis have also been reported as significantly more frequent in CIMC than in other mammary tumor types [16] .
In humans, primary IBC develops de novo in a previously normal breast ( Figure   1B ); while secondary IBC is characterized by a distinct presentation of the disease, with a diffuse chest wall rash or nodules that may quickly form ulcers ( Figure 1A and C) . This form of IBC can be present in patients with a history of non-inflammatory disease in the chest wall [27] . Another presentation of IBC, termed clinically occult, is described by the absence of clinical signs of inflammation in patients with aggressive breast cancer with histologically confirmed invasion of the dermal lymphatics by tumor emboli [94] . As in humans with a diagnosis of IBC, two clinical forms of CIMC have been described in companion dogs.
Primary CIMC develops without a previous history of mammary nodules, while secondary CIMC occurs after a diagnosis of a mammary tumor, generally forming at the surgical wound site [16] . Two histological patterns of neoplastic dermal infiltration -tubular/papillary and sarcomatous-like -have been observed in CIMC [19] . Finally, histological types might differ, but are generally diagnosed as locally advanced invasive carcinoma of the breast in humans or as anaplastic carcinomas in dogs.
In both species, the histological hallmark of inflammatory carcinomas is the formation of tumor emboli in dermal lymphatics resulting in profuse edema due to the obstruction of lymph drainage (Figure 2A and B) . While emboli are characteristic of IBC, they are not specific [95] . For a correct diagnosis of inflammatory carcinoma, the histopathological diagnosis must be combined with the observation of clinical signs related to exuberant inflammation -tenderness, redness, edema, warmth, firmness [20, 28] Dermal emboli in IBC patients are generally numerous and larger than in patients with non-IBC even though these characteristics present no correlation with the degree of breast-skin redness [5] .
In a retrospective study of Algerian IBC patients, 77% presented dermal emboli, although the presence of tumor emboli was not associated with lymph node metastasis or overall survival [63] . However, the presence of tumor emboli, in 70% of IBC cases (25% local IBC, 45% diffuse IBC; P=.01), was associated with diffuse presentation and 3-fold higher risk of relapse in a study of French-Tunisian IBC patients [96] .
Finally, mild to moderate lymphoplasmocytic infiltration may be noted around some of the lymphovascular perivascular space [20, 27] . Recent data have shown statistically significant increases in tumor-infiltrating lymphocytes in IBC patients, relative to non-IBC, and associations with TNBC status and pathologic complete response to neoadjuvant chemotherapy [97, 98] Vasculogenic mimicry, the formation of vascular channels lined by tumor cells mimicking endothelial cells, is another characteristic identified in both IBC and CIMC [99, 100] , and it seems to reflect the exuberant angiogenic events taking place. In WIBC-9 xenografts, a model of human IBC, vasculogenic mimicry, induced by angiogenic factors, was identified in hypoxic areas at the center of the tumors where vascular channels form independently of endothelial cells [99] . Studies have highlighted the intensive lymphangiogenesis and angiogenesis, contributing to the high metastatic potential of IBC [17, 37, 51, 101] and CIMC [19, 102, 103] . To illustrate this, expression of CD31, an endothelial cell marker used to evaluate microvessel density as a measurement of neoangiogenesis, is shown for both IMC and CIMC in Figure 2 , C and D respectively. A summary of comparative clinical signs, histologic and pathologic findings in CIMC and IBC is presented in 
Clinical management
Standard of care treatment
Currently, for patients diagnosed with IBC, a multidisciplinary treatment involves
(1) neoadjuvant systemic therapy with a taxane plus anthracycline chemotherapy adding a HER2 targeted therapy for HER+ tumors; (2) followed by total mastectomy with level l/ll axillary dissection; and (3) adjuvant radiation therapy to the chest wall and draining lymphatics; with (4) possible delayed breast reconstruction and (5) completion of chemotherapy if not completed pre-operatively with endocrine therapy if either ER or PR positive and possible continuation of HER2-directed therapy [45] . Alternative therapeutic options have been suggested, including preoperative primary systemic chemotherapies with a docetaxel-epirubicin protocol with curative intent, which was demonstrated to lead to equivalent outcomes as anthracycline-containing protocols [104] . A 20-year follow-up study has also evaluated the possibility of combining only chemotherapy plus hormonal therapy and radiation in cases of nonmetastatic IBC, maintaining survival rates comparable to the standard-of-care treatment [105] .
The preferred treatment option for CMT is the surgical excision of the mammary glands [26] . However, for CIMC, as with invasive mammary carcinomas, neoadjuvant chemotherapy and/or palliative treatments might be preferable. Due to the diffuse presentation of CIMC and extensive inflammation, with difficult definition of surgical margins, incomplete excision is a risk too frequently taken [106] .
There is no consensus for a neoadjuvant chemotherapy protocol for CIMC. One clinical study revealed a clinical benefit on the prognosis of dogs with CIMC treated with piroxicam, a nonselective COX-2 inhibitor, alone or in combination with other chemotherapeutic drugs such as carboplatin, doxorubicin, capecitabine or cisplatin [6] . A positive response to piroxicam treatment was also observed in a group of 7 dogs with CIMC, in which the CIMC-associated clinical signs were visibly reduced and survival times increased relative to doxorubicin-treated animals [107] . Another study explored the effect on the overall survival time in dogs undergoing palliative treatment with piroxicam and antibiotics versus a combination of palliative and chemotherapeutic treatments combining mitoxantrone, vincristine and cyclophosphamide intravenously or giving mitoxantrone alone.
No statistically significant differences were observed between the two groups, although dogs given chemotherapeutic treatment had longer mean survival times (57 days) than dogs on palliative treatment (32 days) [108] . However, large-scale clinical trials are needed to validate these different modalities and establish guidelines for recommended therapeutic approaches for CIMC. Despite short overall survival, improved quality of life and slightly slower disease progression were observed with metronomic chemotherapy protocols using chlorambucil and firocoxib (a selective COX-2 inhibitor) [109] .
Targeted therapies
Targeted crizotinib, an ALK and ROS1 inhibitor, was proven using mice bearing IBC xenografts. In the MaryX model Crizotinib induced apoptosis and reduced ALK expression [112] . The efficacy of this regimen in IBC will need to be explored.. Other potential therapeutic targets currently under preclinical investigation in IBC are E-cadherin and RhoC GTPase, therapies that ideally would be integrated in large-scale, multicenter cohort studies [5] . However, positive preclinical evaluations in cell lines and rodent models are often difficult to translate into positive clinical benefit in patients. This suggests that a more appropriate model system, such as dogs with CIMC, may be valuable as a more predictive preclinical model.
To our knowledge there are no targeted therapies available for dogs with CIMC, albeit this reality could be transformed in coming years with the development of personalized antibody therapy for canine patients. Recent data showing an acceptabel safety profile with the anti-PD1 and PD-L1 monoclonal antibody-therapy used in humans with very limited activity in heavily pretreated advanced, triple-negative breast cancer [113, 114] ,offers dogs as a possible model for evaluating immunotherapy combinations with hopefully greater activity [115] . Preliminary studies assessing PD-L1 and PD1 expression in a wide range of canine malignancies, has found PD-L1 positivity in malignant CMT among others, suggesting assessment of the PD-1/PD-L1 axis as a therapeutic target can be pursued, particularly for canine oral melanoma where PD1 expressing T-cells were also observed. [116, 117] .
Following the recent trend in human cancer immunotherapy, most therapeutic monoclonal antibodies in veterinary oncology remain under investigation and pre-clinical development [118] . Presently, the FDA has only licensed anti-CD20 and CD52 chimeric monoclonal antibodies for treatment of canine B and T-cell lymphomas, respectively [119] . Progress toward improved therapeutic options for CIMC will require clinical studies able to test combination protocols and novel therapeutic targets. A summary of the clinical management options for CIMC and IBC is presented in [26, 106]  No consensus on neoadjuvant therapy. Use of COX-2 inhibitors alone or in combination with chemotherapy has been reported [6, [110] [111] [112]  Multidisciplinary treatment with taxane-anthracycline-based neoadjuvant chemotherapy, followed by modified radical mastectomy and adjuvant radiation therapy to the chest wall and draining lymphatics [45] Targeted therapies  Research and development of targeted therapies for CIMC is still ongoing.
 Neoadjuvant anti-VEGF (bevacizumab) plus trastuzumab in HER2-positive cases [47, 110]  Anti-EGFR (panitumumab) under evaluation in clinical trial (NCT01036087).
Prognostic factors
Despite the increased understanding of IBC and the multidisciplinary therapeutic approach, women diagnosed with IBC continue to have mortality rates that are higher than those women with non-inflammatory locally advanced breast cancer [5, 111, 120] . Similarly, the prognosis for dogs with CIMC remains poor and overall survival times range between weeks to only a few months [6, 16] . Dogs receiving chemotherapeuty plus and a non-selective COX-2 inhibitor have shown significantly increased survival times relative to dogs receiving only palliative treatment [6] . However, large-scale clinical trials are warranted to confirm these findings in CIMC. A summary of the prognostic factors in IBC and suggested biomarkers warranting prognostic studies in CIMC is presented on table 6. Prognostic studies in dogs with CIMC are challenging due to the fact that most animals will eventually be euthanized given the severity of the clinical signs presented, instead of dying from advanced metastatic disease.
Endocrine and HER2 receptors, chemokine receptors and epidermal growth factors
In many cases of IBC, the triple-negative status drastically limits the treatment options and impacts negatively impacts patient prognosis [48] . In a retrospective study analyzing of 2,014 women diagnosed with IBC, hormone receptor (ER, PR) positive status was found to be associated with improved overall survival and breast cancer-specific survival (N=626; HR=0.55, 95% CI=0.47-0.65; P<.05) whereas HER2-positive status (N=703; HR=0.82, 95% CI = 0.68 to 0.99, NS) was not [125] . Other authors have confirmed the lack of prognostic value of HER2 receptor in IBC [121, 122] . However, in patients with HER2-positive tumors, treatment with trastuzumab confers benefit and improved survival times compared to HER2-negative patients [121] . It is possible that other molecules in IBC, such as E-cadherin [92, 123] , RhoC GTPase and WISP3 [39, 124, 125] may have a greater role in the mechanisms of IBC metastatic invasion, angiogenesis and tumor growth than the HER2 receptor and that targeting these molecules could have a greater impact on the prognosis.
Expression of the chemokine receptors CCR7 and CXCR4, previously associated with breast cancer metastasis [126] has been characterized in IBC. In one study, 40.9% and 23% of IBC cases had expression of CXCR4 and CCR7, respectively.. However, only concurrent expression levels of CXCR4 and CCR7 was associated with a trend for shorter overall survival, and this did not reach statistical significance [50] .
EGFR pathway activity, defined as the aggregate expression of a group of genes linked to EGFR signaling, is significantly lower in IBC patients who achieve a complete pathological response than in those with residual disease after neoadjuvant, anthracyclinebased chemotherapy (P=.02) [93] . In CIMC, EGFR protein expression is high in tumor tissue homogenates and significantly increased relative to malignant CMT, benign CMT and nonneoplastic mammary gland (P<.001). Therefore, incremental EGFR expression is proposed to have a role in the development of CIMC, but this hypothesis needs to be investigated mechanistically [127] . Representative EGFR expression in IBC and CIMC cases is shown on Figure 2 G and H, respectively.
Cyclooxygenase-2
The cyclooxygenase-2 (COX2)/prostaglandin E2 pathway is widely recognized for its role in driving mammary carcinogenesis as an inflammatory mediator and as a promoter of angiogenesis, metastasis and invasion in rodent models of mammary carcinogenesis [128, 129] . In IBC, however, COX-2 expression and its prognostic value have been understudied. In vitro experiments have shown higher COX-2 expression in cancer stem cell tumorspheres of the IBC cell line SUM149 relative to the non-IBC cell line MCF-7, suggesting a role for COX-2 in stem cell formation and possibly a role in the inflammatory microenvironment of IBC [130] . In CIMC, high levels of COX-2 have been found relative to non-CIMC tumors [18] . There is a positive association of COX-2 with high VEGF-D and VEGFR levels, and the lymphatic proliferation index, supporting the involvement of COX-2 in the lymphangiogenic mechanisms of CIMC [131] . Illustrative expression of COX-2 in IBC and CIMC is shown in Figure 2 , images E and F respectively.
Vascular endothelial growth factor
Because IBC and CIMC require high levels of angiogenesis as part of their rapidly growing and invasive phenotype [37, 101] , it was expected that the expression of vascular endothelial growth factor (VEGF-A) is expected to be high. Interestingly, high expression of VEGF-A was found but this was noted in the stromal, but not in the epithelial cells of the tumor, and this was associated with poor disease-free and breast cancer-specific survival in patients with a diagnosis of IBC [51] . In CIMC, augmented tumoral VEGF expression has been reported, but its prognostic value has not been evaluated [102, 131, 132] .
Other prognostic factors
More recently, innovative techniques have been applied to allow earlier prediction of metastatic risk in IBC patients. One study explored the predictive value of microscopic image analysis of histopathology sections at the time of diagnosis [133] . By applying the GrayLevel Co-Occurrence Matrix (GLCM) method, parameters of tissue heterogeneity, such as entropy and contrast, were able to predict metastasis outcome more efficiently than commonly used clinical variables. This technique could help to prioritize and select patients with higher metastatic risk for targeted therapies.
Additionally, the number of circulating tumor cells (CTCs) (1) in patients with stage III IBC patients has also been identified as a good predictor of recurrence after primary systemic therapy, modified radical mastectomy, postoperative radiotherapy and trastuzumab neoadjuvant treatment for HER2 + patients [134] . If further confirmed, CTCs could be used to select patients at high risk of relapse. While the presence and prognostic role of CTCs in CIMC is unknown, the findings in humans with IBC warrant studies in CIMC. [125] Chemokine receptors   Concurrent CXCR4 and CCR7 expression associated with trend in shorter OS [50] .
Epidermal growth factor (EGFR)  Role for EGFR in CIMC progression has been suggested but prognostic studies are warranted [127]  EGFR pathway activity is lower in patients with complete pathological response [93] Cyclooxygenase-2 (COX-2)  COX-2 associated with VEGFR levels, and the lymphatic proliferation index, supporting the involvement of COX-2 in the lymphangiogenic mechanisms of CIMC [131] . Prognostic studies are warranted  Prognostic studies are warranted VEGF  Tumoral VEGF is expressed in CIMC but prognostic value has not been assessed [102, 131, 132]  Stromal VEGF-A associated with poor DFS and BCSS [51] Others  Entropy, contrast and other parameters of tissue heterogeneity can predict metastasis [133] .
 CTCs1 predicts recurrence in HER2 + IBC patients after multimodal therapy [134] OS -overall survival, DFS -disease free survival, BCSS -breast cancer specific survival, CTCsCirculating tumor cells
Conclusion and future perspectives (5-year horizon)
For both humans and dogs, the aggressiveness and lethality of IBC and CIMC, compared to other breast cancer types demands a concerted multidisciplinary effort to identify novel and specific therapeutic options and prognostic factors to help categorize patients and provide better treatments. The fundamental similarities between human IBC and CIMC underlie the value of comparative and translational research for the benefit of both species. Advances in understanding the pathogenesis of both diseases and the development of genome-based molecular and immunological reagents, as well as commercially available high-throughput methodologies such as next-generation sequencing or multiple-cytokine array assays specific for dogs, will enhance our ability to deeply interrogate canine cancers and characterize shared and novel targets for novel therapeutic interventions.
A major challenge of therapeutic development in oncology is the design of clinical trials, often based solely on previous research using rodent models. We would argue CIMC could serve as an intermediate preclinical model between rodent models and humans prior to the design and execution of clinical trials. A canine preclinical model could enable a better understanding of the mechanism of action of a novel intervention, dosing, administration and could potentially improve clinical trial design and hopefully increase success rates while reducing expense. Furthermore, the development of therapies in canines would also serve the animal patients and their owners. Current therapies for canine cancers, as noted above for CIMC, are often not a cost-effective option. The opportunity to perform well-designed and innovative therapy trials at minimal expense for dog owners and researchers would provide canine patients and their owners access to the best therapeutic options while also contributing to improvement in the therapy of human cancer. Additional advantages to using a spontaneous canine model in preclinical studies include the short lifespan after diagnosis that offers the opportunity to accelerate endpoints of clinical trials and the exposure to environmental pollutants that renders dogs as suitable sentinels. While not advocated as a replacement for toxicokinetic studies in rodent models, comparative oncology studies performed in dogs have the potential to provide information not easily obtained by conventional preclinical models prior to human trials [2] . Finally, the existence of CIMC cell lines might facilitate in vitro screening of new therapeutic drugs in preclinical studies for CIMC [23] ,providing another strategy to further reduce the time and cost of preclinical development. Although testing of novel CIMC therapies can begin immediately, CIMC as a model for IBC could be further optimized with additional comparative studies evaluating immunohistochemical expression of prognostic markers and gene expression profiles.
We envision that immunotherapeutic strategies will start to be employed for the treatment of canine cancers, including CIMC. In these animals, genetically variable tumors develop spontaneously in a syngeneic environment and in the presence of an intact immune system in an aging animal, thus making dogs diagnosed with CIMC ideal models to research new treatments for this highly metastatic and deadly tumor. Upcoming production of novel therapeutic monoclonal antibodies against biomarkers with prognostic significance could rapidly provide dogs with state-of-the-art therapy and, in parallel, generate clinically relevant new data with direct applicability to subsequent human clinical trial studies.
Given the highly metastatic nature of IBC and CIMC, knowledge obtained about this cancer type could be applied to the management of other highly aggressive epithelial cancer types. In addition, the discovery of new therapeutic targets may provide new opportunities for the treatment of this aggressive disease in both humans and canines. Prospectively, further research is warranted for a better understanding of the biology of IBC and CIMC by identification of specific molecular determinants and the subsequent innovative design of targeted therapies that could halt the metastatic process and hopefully improve outcomes for patients with both IBC and CIMC. 
